Immunocore Holdings Ltd (IMCR) Stock Analysis

Immunocore Holdings Ltd (IMCR) is a publicly traded company in the HEALTHCARE sector. It trades at $29.56, carries a market capitalization of $1.47B. This page summarizes the public market data, fundamentals, and frequently asked questions for IMCR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $29.56
• Market Cap: $1.47B
• EPS: $-0.56
• 52-Week High: $40.71
• 52-Week Low: $27.55

Market Sentiment

Immunocore Holdings Ltd currently has a Bullish sentiment score of 0.33.

About Immunocore Holdings Ltd

Immunocore Holdings Limited is a pioneering biotechnology company headquartered in Abingdon, UK, dedicated to the development of cutting-edge immunotherapies for cancer, infectious diseases, and autoimmune disorders. Utilizing its proprietary T cell receptor technology, Immunocore aims to harness and amplify the body’s immune response, driving forward transformative treatment options with the potential to significantly enhance patient outcomes. The company boasts a solid pipeline of clinical ...

GNG Research Analysis

GNG Research scores Immunocore Holdings Ltd (IMCR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IMCR.

Frequently Asked Questions

Does IMCR pay dividends?

Immunocore Holdings Ltd (IMCR) does not currently pay a regular dividend.

What is IMCR's market cap?

Immunocore Holdings Ltd (IMCR) has a market capitalization of $1.47B with a current stock price of $29.56.